This study aims to investigate the impact of maternal amphetamine use during pregnancy on neonatal birth weight. Specifically, the study is focused on infants born to women who had a positive amphetamine test at delivery, and aims to explore whether maternal amphetamine use is associated with lower birth weights in their infants Amphetamines Pregnancy Birth Weight Infant, Newborn Retrospective Studies Multi-Site Studies Substance-Related Disorders
Conditions
Interventions
Sponsors
None listed
Eligibility
Inclusion criteria
Inclusion criteria: Women who gave birth at the participating hospitals during the study period. Women who underwent drug testing during pregnancy or at delivery. Women who tested positive for amphetamines at delivery (positive test group). Women who tested negative for amphetamines during pregnancy or at delivery (non-positive test group). Infants born to the included women. Infants born between a specific time period (January 1, 2021 to March 31, 2023) Infants born at one of the participating hospitals or labor rooms included in the study Infants born at or after 24 weeks gestational age
Exclusion criteria
Exclusion criteria: Women who did not undergo drug testing during pregnancy or at delivery. Women who tested positive for other drugs of abuse, such as cocaine or opioids. Women with pre-existing medical conditions that could affect neonatal birth weight, such as hypertension or diabetes. Infants with known congenital anomalies or medical conditions that could affect birth weight, such as intrauterine growth restriction or multiple gestations. Infants with missing or incomplete birth weight data.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| the birth weights at the time of birth birth weight is typically measured in units of mass, such as grams | — |
Secondary
| Measure | Time frame |
|---|---|
| N/A N/A N/A | — |
Countries
Thailand
Contacts
Chiangkhan Hospital